Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04069273 · ClinicalTrials.gov registry record · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
A Phase 2 study of Gastric Cancer and Adenocarcinoma, sponsored by Harry H Yoon.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 2
- Study locations
NCT04069273: Recruiting Phase 2 study of Gastric Cancer and Adenocarcinoma, sponsored by Harry H Yoon.
NCT04069273 is a Phase 2 study of Gastric Cancer and Adenocarcinoma that is actively recruiting participants, run by Harry H Yoon. The registered enrollment target is 58 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04069273, a Phase 2 study of Gastric Cancer and Adenocarcinoma, is actively recruiting participants, sponsored by Harry H Yoon.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 2
- Study locations
Study Summary
Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with paclitaxel reactions. Cohort 2 Patients are randomized to Arm A or B. Treatment in both arms includes pembrolizumab + RAM + paclitaxel.
Primary Outcome
BORR is defined as the number of best responses (including rates of complete response \[CR\], partial response \[PR\], disease control \[DCR\], stable disease \[SD\], progressive disease \[PD\]) divided by the total number of evaluable patients. Evaluate the BORR of combined ramucirumab (RAM) plus paclitaxel (with differing schedules of pembrolizumab \[PEM\]) following induction of PEM in patients with advanced gastric and GEJ adenocarcinoma pooling Arm A and B.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Ramucirumab
- DRUG Pembrolizumab Monotherapy
Study Locations (2)
Minnesota
- Mayo Clinic- Minnesota - Rochester
Wisconsin
- Froedtert and The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2026-12-10 |
| Phase | Phase 2 |
What NCT04069273 shows while recruiting
NCT04069273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Paclitaxel is the first listed.
NCT04069273 reports a single indexed study location in Minnesota, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04069273 about?
NCT04069273 is a clinical study titled "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma". Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with pacl...
What is the current status of trial NCT04069273?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2020-12-01. Estimated completion is 2026-12-10.
What conditions does trial NCT04069273 study?
This clinical trial studies the following conditions: Gastric Cancer, Adenocarcinoma, GastroEsophageal Cancer.
What interventions are being tested in trial NCT04069273?
The interventions under investigation include: Paclitaxel (DRUG), Ramucirumab (DRUG), Pembrolizumab Monotherapy (DRUG).
Who is sponsoring clinical trial NCT04069273?
This trial is sponsored by Harry H Yoon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04069273 being conducted?
This trial has 2 study locations across Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04069273's enrollment target sits among peer trials
58 112th of 153 higher than 41 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04373473 · 58 participants · Phase 2
Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI